View Risk


Article data
Mehta (2020)
Association of Use of Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers With Testing Positive for Coronavirus Disease 2019 (COVID-19)
10.1001/jamacardio.2020.1855
https://jamanetwork.com/journals/jamacardiology/fullarticle/2765695?utm_campaign=articlePDF%26utm_medium%3darticlePDFlink%26utm_source%3darticlePDF%26utm_content%3djamacardio.2020.1855

Results
Treatment
Concomitant medication (Treated with ARBs vs. Not received)
COVID-19 (any condition)
Odds ratio: 1.610 (1.040-2.500) Adjusted model

Study characteristics

United States of America

Retrospective cohort study

Medical records

18472

patients tested for COVID-19

The mean (SD) age was 49 (21) years, 7384 (40%) were male, and 12 725 (69%) were white. Of 18 472 patients who underwent COVID-19 testing, 2285 (12.4%) were taking either ACEIs or ARBs. A positive COVID-19 test result was observed in 1735 of 18 472 patients (9.4%). Among patients who tested positive, 421 (24.3%) were admitted to the hospital, 161 (9.3%) were admitted to an intensive care unit, and 111 (6.4%) required mechanical ventilation.

0


Results

COVID-19 (any condition)

421

Nasopharyngeal and oropharyngeal swab specimens were collected and pooled for testing by trained medical personnel. Infection with SARS-CoV-2 was confirmed by laboratory testingusing the Centers forDisease Control andPrevention reverse transcription–polymerase chain reactionSARS-CoV-2 assay

Treatment

Concomitant medication

arb

Not received

Treated with ARBs

Odds ratio

1.610 (1.040-2.500)

No

Yes

Yes

Propensity Score Weighted–Analysis ORs : age, sex, and presence of hypertension, diabetes, coronary artery disease, heart failure, and chronic obstructive pulmonary disease


Other information

none

Average

No

Go Back